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Background: Polymyositis and dermatomyositis-associated interstitial lung disease (PM/DM-ILD)
can have variable courses. We evaluated the prognostic value of high-resolution computed
tomography (HRCT) in PM/DM-ILD.
Methods: The cases of 51 patients newly diagnosed with PM/DM-ILD were retrospectively
reviewed. HRCT images at diagnosis were categorized into four radiological patterns based
on the major findings and distributions of these abnormalities, and the disease extent on HRCT
was scored. The impact of HRCT findings and other clinical parameters on day 90 and overall
mortality were analyzed.t of Rehabilitation Medicine, Kyoto University Hospital, 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto
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oo.co.jp, hanta@kuhp.kyoto-u.ac.jp (T. Handa).
3 Elsevier Ltd. All rights reserved.
3.01.014
746 K. Tanizawa et al.tomography;
Interstitial lung
disease;
PolymyositisResults: Of the 51 patients (11 with polymyositis and 40 with dermatomyositis), the lower
consolidation/ground-glass attenuation (GGA) pattern was observed in 21 patients (41%), lower
reticulation was observed in 23 patients (45%), random GGA was observed in four patients (8%),
and other patterns were observed in three patients (6%). Twenty-one patients (42%) were pos-
itive for anti-CADM-140. The lower consolidation/GGA pattern, clinically amyopathic dermato-
myositis, fever (38.0 C), ferritin levels >500 ng/mL, and the presence of anti-CADM-140 were
significantly associated with 90-day mortality in univariate analysis. Multivariate analysis re-
vealed that the lower consolidation/GGA pattern (odds ratio, 23.1; PZ 0.02) and the presence
of anti-CADM-140 (odds ratio, 14.1; PZ 0.03) were independent predictors of 90-day mortality.
This HRCT pattern was also associated with a higher 90-day morality rate among anti-CADM-
140-positive patients. The lower consolidation/GGA pattern was also associated with overall
mortality in univariate analysis, whereas only the presence of anti-CADM-140 was an indepen-
dent determinant of overall mortality in multivariate analysis.
Conclusion: HRCT patterns at diagnosis can help predict the prognosis of patients with PM/DM-
ILD as well as the presence of anti-CADM-140.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Polymyositis (PM) and dermatomyositis (DM) are auto-
immune disorders that can affect muscles, skin, and lungs.1
Interstitial lung disease (ILD) is a significant prognostic
factor in PM/DM patients,2 but the course of PM/DM-
associated ILD (PM/DM-ILD) is variable. PM/DM-ILD can be
classified as acute or chronic. Acute ILD is often rapidly
progressive and fatal.3 Thus, in the management of PM/DM-
ILD patients, it is critical to predict the outcome of each
case and to identify emergent and high-risk cases at
diagnosis.
Pretreatment prognostic factors in PM/DM-ILD have been
sought through clinical and serological evaluations. Clin-
ically amyopathic dermatomyositis (C-ADM) is a subtype of
DM with little or no evidence of muscular manifestations
that has been reported to be associated with worse prog-
nosis in the Japanese population.4 PM/DM is also charac-
terized by serum autoantibodies specific to PM/DM,
designated myositis-specific antibodies (MSAs).5 Among
MSAs, anti-CADM-140 antibody (anti-CADM-140) is asso-
ciated with high mortality,6 and a worse prognosis com-
pared to anti-aminoacyl-tRNA synthetase (ARS) antibodies
(anti-ARS).7
Recently, we reported that high-resolution computed
tomography (HRCT) patterns at diagnosis were significantly
different between anti-CADM-140-positive and -negative
cases of DM-ILD.8 Given the significant association of anti-
CADM-140 with survival,6,7 we speculated that HRCT pat-
terns would be associated with the prognosis of PM/DM-ILD
patients. Furthermore, the disease extent on HRCT was
reported to be the predictor of mortality in other ILDs such
as idiopathic pulmonary fibrosis (IPF),9 idiopathic fibrotic
interstitial pneumonia,9 and scleroderma-associated ILD
(SSc-ILD).10 These findings raise the hypothesis that HRCT
evaluation at diagnosis can help predict the outcome of
PM/DM-ILD.
Thus, the aim of the present study was to elucidate the
prognostic value of radiological patterns and disease extent
on HRCT at diagnosis in PM/DM-ILD. We expanded our pre-
vious study cohort by conducting a retrospective study andsought to define the utility of HRCT evaluation in predicting
prognosis.
Methods
Patients
The study population was comprised 51 patients diagnosed
with PM/DM-ILD at Kyoto University Hospital and Tenri
Hospital, a tertiary care center, from January 2005 to April
2011. PM and DM were diagnosed using the Bohan and Peter
criteria,11 and ILD was diagnosed by HRCT. C-ADM was
diagnosed if a patient had the characteristic skin rash of DM
but little/no muscle symptoms and a serum creatine kinase
(CK) level <300 IU/L at diagnosis.6 Patients were excluded
if they had an active neoplasm or other connective tissue
diseases, or had been treated with systemic corticosteroids
or immunosuppressive agents before referral to our hospi-
tals. Of the 51 patients with PM/DM-ILD, 25 had been
included in our previous study.8 The Kyoto University Hos-
pital Institutional Review Board and the Tenri Hospital
Institutional Review Board approved this study.
Clinical evaluation
Clinical information was retrospectively collected from
medical records. The 90-day mortality and overall survival
were assessed as the short- and long-term prognoses,
respectively. All patients were evaluated by at least two
rheumatologists prior to treatment and had blood tests at
their first visit. The patients also underwent standardized
pulmonary function tests,12 and published equations for
Japanese adults were used to determine predicted values
for each parameter.13
Measurement of MSAs
Serum samples were obtained from all patients at the first
visit prior to immunosuppressive therapy. The presence of
MSAs was determined by protein-immunoprecipitation
Prognosis and HRCT evaluation in PM/DM-ILD 747(Protein-IPP) for anti-CADM-140, anti-p155/140, anti-Mi2,
and anti-Ku antibodies, and RNA-immunoprecipitation
(RNA-IPP) for anti-ARS (anti-Jo-1, anti-PL7, anti-EJ, anti-
OJ, anti-PL12, and anti-KS) and anti-signal recognition
particle (SRP) antibodies, as described previously.6,14
HRCT evaluation
All patients underwent chest HRCT prior to treatment, and
three independent observers (T.K., T.H., and K.T.) blinded
to the clinical information reviewed the HRCT images and
resolved inter-observer disagreements by consensus.
All 51 cases were categorized by HRCT pattern, as
described previously.8 The HRCT pattern of each case was
defined based on the dominant CT findings and the cra-
niocaudal and axial distributions of these findings. The
dominant finding was classified as ground-glass attenuation
(GGA), consolidation, or reticulation (intralobular reticular
opacities, interlobular septal thickening, or nonseptal lin-
ear or plate-like opacity). The craniocaudal distribution
was assessed as upper, lower, diffuse, or random. Upper
distribution was defined as extensive findings predomi-
nantly above the level of the inferior pulmonary veins, and
lower distribution as findings predominantly below this
level. The distribution was defined as diffuse when the
findings were generalized, and as random when there was
no zonal predominance. Axial distribution was classified as
peribronchovascular when the dominant findings were
along the bronchi and vessels, and as peripheral when the
findings were in the outer one-third of the lung. Axial dis-
tribution was classified as diffuse when the findings were
generalized and as random when no distribution pattern
was apparent.
HRCT scoring
The extent of ILD-characteristic abnormalities on HRCT in
each case was evaluated according to Goh’s scoring system
for scleroderma.10 Briefly, the extent of alveolar (GGA and
consolidation), fibrotic (reticulation), and total abnormal-
ities were scored to the nearest 5% in each of the following
five sections: origin of great vessels, main carina, pulmo-
nary venous confluence, halfway between the third and
fifth section, and immediately above the right hemi-
diaphragm. The global extent of the abnormalities was
computed as the mean of the scores. Two independent
observers (K.T. and K.A.) blinded to the clinical information
reviewed the HRCT images and resolved inter-observer
disagreements by consensus.
Statistical analyses
Statistical analyses were performed using JMP version 9.0
(SAS Institute Inc. Cary, NC, USA). All statistical variations
in quantitative data were expressed as a single determi-
nation standard deviation, and P < 0.05 was considered to
indicate statistical significance.
Group comparisons were made using Fisher’s exact test,
the ManneWhitney U test, or the KruskaleWallis test. Sur-
vival curves were drawn using the KaplaneMeier method
and compared among groups using the log-rank test.Univariate analyses and multivariate logistic regression
analyses were performed to determine variables that could
predict 90-day mortality. Survival analysis was also per-
formed to define the prognostic value of each variable at
diagnosis. The Cox proportional hazards model was used for
univariate and multivariate analyses. Variables were
entered into models for multivariate analysis if they were
significantly associated with worse prognosis in the pre-
ceding univariate analysis.
Results
Initial clinical features
Demographics, clinical manifestations, and laboratory test
results of study participants at diagnosis are summarized in
Table 1. Among the 51 patients, PM was diagnosed in 11
(22%) and DM in 40 (78%). C-ADM was diagnosed in 18 (45% of
DM) patients. One patient with PM and 20 with DM (41% of
all patients) were positive for anti-CADM-140. One patient
with DM was positive for anti-p155/p140 antibody. Seven
patients with PM and 13 with DM (39% of all patients) were
positive for anti-ARS antibodies: anti-Jo-1 in 9, anti-PL7 in
4, anti-EJ in 3, anti-OJ in 2, anti-PL12 in 1, and unspecified
in 1 patient. Antibodies to SRP, Mi2, and Ku were not
detected in any patients. These MSAs were mutually
exclusive in all MSA-positive patients.
HRCT evaluation and scoring
Through a review of the HRCT images, all 51 cases were
categorized into one of three previously reported HRCT
patterns (lower consolidation/GGA pattern (lower periph-
eral or peribronchovascular consolidations or GGA),
lower reticulation pattern (lower peripheral or peri-
bronchovascular reticulation), and random GGA pattern
(random peripheral GGA)), and cases that did not exhibit
any of these patterns were categorized as “other”.8 Lower
consolidation/GGA pattern was characterized by non-
segmental consolidations or GGA, with subpleural or peri-
bronchovascular distribution. Lower reticulation pattern
showed a homogeneous distribution with some subpleural
sparing. In the random GGA pattern, small GGAs were seen
in a patchy manner in the absence of consolidation.
Lower consolidation/GGA pattern was seen in 21 pa-
tients (41%), lower reticulation in 23 (45%), random GGA in
4 (8%), and other in 3 (6%). Others included one patient with
craniocaudally- and axially-diffuse GGA, one with upper
diffuse GGA, and one with diffuse peripheral reticulation.
The extent of alveolar, fibrotic, and total abnormalities are
shown in Table 1.
Treatment and outcome
All patients received corticosteroid therapy, and 40 patients
(78%) received immunosuppressive agents, usually cyclo-
sporine A (67%). The median follow-up from diagnosis was
714 days (range: 26e2418). All survivors were followed up
for more than 90 days. Characteristics of the 17 non-
survivors are summarized in Table 2. One patient with PM
Table 1 Characteristics of study participants at diagnosis
(n Z 51).
Values Range
Age, years 54.6  11.3 (29e79)
Male 17 (33%)
PM/DM 11/40 (22.6%/78.4%)
C-ADM 18 (35%)
MRC [1e5] 2.7  1.1 (1e5)
Fever 38.0 C 19 (37%)
CK, IU/L
(Normal, 35e141)
1333.7  2488.1 (16e12,466)
Aldolase, IU/L
(Normal, 2.7e5.9)
22.9  33.3 (3.7e153.6)
Ferritin, ng/mL 549.3  1051.1 (6.5e7002)
Anti-CADM-140 antibody 21 (41%)
Anti-ARS antibodies 20 (39%)
%FVC, % 86.7  17.0 (54.1e115.4)
%DLCO, % 57.4  17.2 (30.1e103.0)
HRCT pattern
Lower consolidation/
GGA pattern
21 (41%)
Lower reticulation
pattern
23 (45%)
Random GGA pattern 4 (8%)
Other 3 (6%)
HRCT scores
Alveolar
abnormalities, %
9.5  13.6 (0e86)
Fibrotic
abnormalities, %
5.5  5.8 (0e30)
Total abnormalities, % 12.4  14.4 (1e86)
Treatment
Corticosteroid 51 (100%)
Immunosuppressive
agents
40 (78%)
Cyclosporin A 34 (67%)
Dead/alive 17/34 (33%/67%)
90-day mortality 11 (22%)
Values are presented as means  standard deviation or number
(percentage).
The numbers in square brackets represent the theoretical score
range.
Abbreviations: PM, polymyositis; DM, dermatomyositis; C-ADM,
clinically amyopathic dermatomyositis; MRC, Medical Research
Council dyspnea scale; ARS, aminoacyl-tRNA synthetase; %FVC,
percentage of the predicted forced vital capacity; %DLCO,
percentage of the predicted diffusion capacity for carbon
monoxide; HRCT, high-resolution computed tomography; GGA,
ground-glass attenuation.
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mortality was 22% (11/51), and all deaths within 90 days
were caused by progressive ILD. Two patients with PM and
15 with DM died during the follow-up period. The causes of
overall mortality were progressive ILD in 12, Pneumocystis
jiroveci pneumonia in one, P. jiroveci pneumonia with
sepsis in one, acute exacerbation (AE) of ILD without
infection in one, alveolar hemorrhage after chronic respi-
ratory failure in one, and sudden death in one patient.Determinants of 90-day mortality
Results of logistic regression analysis for 90-day mortality
are presented in Table 3. C-ADM, fever (38.0 C), ferritin
>500 ng/mL, anti-CADM-140, and lower consolidation/GGA
pattern were associated with 90-day mortality on univari-
ate analysis. Dyspnea, physiological indices, and the extent
of alveolar, fibrotic, or total abnormalities were not asso-
ciated with 90-day mortality. Multivariate regression anal-
ysis revealed that lower consolidation/GGA pattern and
anti-CADM-140 were significant independent predictors
of 90-day mortality, whereas C-ADM, fever, and ferritin
>500 ng/mL were not.
Overall survival analysis
Results of survival analysis are presented in Table 4. Fever,
ferritin >500 ng/mL, anti-CADM-140, and lower con-
solidation/GGA pattern were associated with worse prog-
nosis (Fig. 1a). Dyspnea, physiological indices, and the
extent of alveolar, fibrotic, and total abnormalities were
not associated with survival. Multivariate analysis revealed
that anti-CADM-140 was the only independent predictor of
overall mortality.
Relationship between anti-CADM-140 and lower
consolidation/GGA pattern
Anti-CADM-140-positive cases were significantly more fre-
quent in patients with lower consolidation/GGA pattern
(14/21; 67%) than in those without this pattern (7/30; 23%,
P < 0.01). In anti-CADM-140-positive patients, 90-day
mortality was significantly higher in patients with lower
consolidation/GGA pattern (9/14; 64%) than in those with-
out this pattern (1/7; 14%, P Z 0.04). However, overall
survival was similar in patients with and those without this
pattern (log-rank test, P Z 0.46) (Fig. 1b).
Discussion
We demonstrated that lower consolidation/GGA pattern is
a significant determinant of short-term prognosis in PM/DM-
ILD as well as anti-CADM-140 status. Lower consolidation/
GGA pattern was also associated with short-term mortality
in anti-CADM-140-positive patients. To our knowledge, this
is the first study showing the value of HRCT in predicting the
outcome of PM/DM-ILD.
Among clinical, radiological, and physiological indices at
diagnosis, lower consolidation/GGA pattern on HRCT and
the presence of anti-CADM-140 were the strongest pre-
dictors of 90-day mortality. Lower consolidation/GGA pat-
tern may represent organized pneumonia (OP)15,16 or
diffuse alveolar damage (DAD),15e20 although other patho-
logical patterns can be included.20 PM/DM-ILD with OP or
DAD can be complicated by rapidly progressive respiratory
failure that often results in a fatal outcome.21e25 Higher
short-term mortality of patients with the lower con-
solidation/GGA pattern strongly suggests that this HRCT
pattern may include these most aggressive phenotypes of
PM/DM-ILD.
Table 2 Clinical features of non-survivors.
No. Age, years/
gender
Diagnosis Fevera Ferritin,
ng/mL
Anti-
CADM-140
HRCT
pattern
Treatment Durationb,
days
Cause of death
1 69/F DM  1919 þ LR CS, CsA, IVCY 26 Progressive ILD
2 66/F C-ADM þ 169 þ LC/G CS, CsA, IVCY 34 Progressive ILD
3 55/M C-ADM  271  LC/G CS, CsA, IVCY, PE 36 Progressive ILD
4 62/M PM  1976 þ LC/G CS, CsA, IVCY, FK506, PMX 38 Progressive ILD
5 44/M DM þ 7002 þ LC/G CS, CsA, IVCY, FK506, PE,
IVIG, PMX, LCAP
41 Progressive ILD
6 40/F C-ADM þ 175 þ LC/G CS, CsA, IVCY, PMX 43 Progressive ILD
7 59/F C-ADM þ 650 þ LC/G CS, CsA, IVCY, FK506, PE 47 Progressive ILD
8 45/F C-ADM þ 381 þ LC/G CS, CsA, IVCY 52 Progressive ILD
9 60/M C-ADM þ 488 þ LC/G CS, CsA, IVCY, PE, IVIG 64 Progressive ILD
10 50/F DM  698 þ LC/G CS, CsA, IVCY, IVIG, PMX,
Infliximab
74 Progressive ILD
11 51/M C-ADM þ 1020 þ LC/G CS, CsA, IVCY 87 Progressive ILD
12 64/F DM þ 439 þ RG CS, CsA 92 PCP and sepsis
13 71/M DM  322  LR CS, CsA 113 PCP
14 70/F DM þ 177 þ Other CS, CsA 122 Progressive ILD
15 64/F C-ADM þ 438 þ RG CS, CsA, Pirfenidone 133 AE
16 60/M DM  848  LR CS, CsA 1151 DAH
17 68/M PM  244  LR CS, CsA, IVCY, FK506,
Azathioprine
1614 Sudden death
Abbreviations: MSA, myositis-specific antibody; HRCT, high-resolution computed tomography; M, male; F, female; DM, dermatomyositis;
C-ADM, clinically amyopathic dermatomyositis; PM, polymyositis; anti-CADM-140, anti-CADM-140 antibody; LR, lower reticulation pat-
tern; LC/G, lower consolidation/ground-glass attenuation pattern; CS, corticosteroid; CsA, cyclosporine A; IVCY, intravenous cyclo-
phosphamide; PE, plasma exchange; FK506, tacrolimus; PMX, direct hemoperfusion with a polymyxin B-immobilized fiber column; IVIG,
intravenous immunoglobulin; LCAP, leukocytapheresis; ILD, interstitial lung disease; PCP, Pneumocystis jiroveci pneumonia; AE, acute
exacerbation; DAH, diffuse alveolar hemorrhage.
a 38.0 C.
b The follow-up period from the diagnosis.
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ferent from the characteristic HRCT pattern of acute
interstitial pneumonia (AIP),15,17,18 acute respiratory dis-
tress syndrome (ARDS),19 and AE of IPF.26 In AIP and ARDS,
consolidations and GGAs are more diffusely distrib-
uted.15,17e19 In AE of IPF, new alveolar abnormalities are
superimposed on fibrotic changes, and thus, the total ab-
normalities are more extensive.26 As defined previously,
the major abnormalities in the lower consolidation/GGA
pattern are predominantly localized to the peripheral and
peribronchovascular regions in the lower lung fields.8 Dif-
fuse GGA or consolidation pattern, which was defined
differently from the lower consolidation/GGA pattern, was
observed in only two (4%) of our 51 patients. Furthermore,
physiological impairment or the disease extent on HRCT
was not associated with short- or long-term mortality.
These findings indicate that the disease severity at diag-
nosis cannot account for the mortality of PM/DM-ILD pa-
tients. Rather, unresponsiveness to the initial treatment
may be the culprit in short-term mortality. Indeed, all
deaths within 90 days were caused by progressive ILD,
although the disease was not diffusely distributed at
diagnosis.
In our previous and present studies, the lower con-
solidation/GGA pattern was significantly associated with
anti-CADM-140.8 As anti-CADM-140 was reported to be
associated with worse prognosis in PM/DM-ILD,6,7 highershort-term mortality of patients with lower consolidation/
GGA pattern may reflect the higher frequency of anti-
CADM-140-positive cases. On the other hand, multivariate
analysis revealed that the lower consolidation/GGA pattern
was a significant predictor of 90-day mortality independent
of anti-CADM-140. Indeed, this HRCT pattern was also
associated with higher 90-day mortality in anti-CADM-140-
positive patients, indicating the additional prognostic value
of this HRCT pattern.
The lower consolidation/GGA pattern was also asso-
ciated with overall survival with univariate analysis. How-
ever, multivariate analysis revealed that anti-CADM was the
only independent predictor of long-term mortality. These
results may be due to the fact that all non-survivors with
the lower consolidation/GGA pattern died within 90 days of
diagnosis, whereas anti-CADM-140-positive patients with
other HRCT patterns died after the initial 90 days (Table 2).
On the other hand, long-term outcome can be affected by
various complications such as infection and AE.27e29
Because approximately two-thirds of non-survivors (11/17)
in our study died within the initial 90 days, the period of
follow-up may not be long enough to define the risk factors
for these late complications and address the long-term
prognosis.
In contrast to HRCT patterns, the disease extent on
HRCT had no prognostic value in PM/DM-ILD. Our results
contrast with those reported in IPF9 and SSc-ILD.10 In IPF,
Table 3 Logistic regression analysis for 90-day mortality.
Odds
ratio
95% CI P value
Univariate
C-ADM 4.61 (1.17e20.7) 0.03
MRC 0.91 (0.50e1.69) 0.75
Fever 38.0 C 4.08 (1.04e18.2) 0.04
Ferritin >500 ng/mL 6.80 (1.60e31.6) 0.01
Anti-CADM-140 antibody 26.4 (4.32e513.5) <0.01
%FVC 0.97 (0.92e1.01) 0.14
%DLCO 0.97 (0.91e1.02) 0.27
Lower consolidation/
GGA pattern
26.4 (4.32e513.5) <0.01
Alveolar abnormalities
extent
1.00 (0.93e1.04) 0.90
Fibrotic abnormalities
extent
1.05 (0.94e1.17) 0.34
Total abnormalities
extent
1.00 (0.94e1.04) 0.90
Multivariate
C-ADM 0.63 (0.02e22.6) 0.78
Fever 38.0 C 2.08 (0.28e18.4) 0.48
Ferritin >500 ng/mL 2.73 (0.24e67.0) 0.43
Anti-CADM-140
antibody
14.1 (1.28e505.8) 0.03
Lower consolidation/
GGA pattern
23.0 (1.71e1112.5) 0.02
Abbreviations: 95% CI, 95% confidence interval; C-ADM, clin-
ically amyopathic dermatomyositis; MRC, Medical Research
Council dyspnea scale; %FVC, percentage of the predicted
forced vital capacity; %DLCO, percentage of the predicted dif-
fusion capacity for carbon monoxide; GGA, ground-glass
attenuation.
Table 4 Overall survival analysis.
Hazard
ratio
95% CI P value
Univariate
C-ADM 1.88 (0.70e4.92) 0.20
MRC 1.06 (0.14e6.32) 0.95
Fever 38.0 C 2.86 (1.09e7.90) 0.03
Ferritin >500 ng/mL 3.22 (1.16e8.47) 0.03
Anti-CADM-140 antibody 7.47 (4.32e513.5) <0.01
%FVC 0.99 (0.96e1.02) 0.38
%DLCO 0.97 (0.94e1.01) 0.13
Lower consolidation/
GGA pattern
3.01 (1.14e8.36) 0.03
Random GGA pattern 1.28 (0.20e4.59) 0.75
Alveolar abnormalities
extent
0.99 (0.94e1.02) 0.69
Fibrotic abnormalities
extent
1.04 (0.97e1.10) 0.27
Total abnormalities
extent
0.99 (0.95e1.02) 0.69
Multivariate
Fever 38.0 C 1.59 (0.51e5.03) 0.59
Ferritin >500 ng/mL 1.37 (0.44e4.17) 0.58
Anti-CADM-140 antibody 4.97 (1.55e19.3) 0.01
Lower consolidation/
GGA pattern
1.88 (0.65e5.62) 0.24
Abbreviations: 95% CI, 95% confidence interval; C-ADM, clin-
ically amyopathic dermatomyositis; MRC, Medical Research
Council dyspnea scale; %FVC, percentage of the predicted
forced vital capacity; %DLCO, percentage of the predicted dif-
fusion capacity for carbon monoxide; GGA, ground-glass
attenuation.
750 K. Tanizawa et al.the prognostic value of the HRCT visual score has been
established9 and used for grading severity.30,31 In SSc-ILD,
disease extent on HRCT was reported to be a significant
predictor of mortality.10 These differences between
PM/DM-ILD and other ILDs may be due to the fact that
PM/DM-ILD may include more heterogeneous diseases than
IPF and SSc-ILD. The variety of PM/DM-ILD has been dem-
onstrated in terms of clinical course,20,24 subtypes,4,32 and
HRCT patterns.8,20 It may be difficult to apply a single HRCT
scoring system to PM/DM-ILD patients with different radi-
ological patterns.
Phenotypes of PM/DM-ILD may be different among dif-
ferent ethnic groups. C-ADM, a characteristic subtype of DM
has been associated with worse prognosis in the Japanese
population,4,22,24 whereas Cottin et al. reported favorable
prognosis of C-ADM in the Western population.32 The fre-
quency of C-ADM may be also higher among the Japanese
than Western populations.4,24,32 Furthermore, most anti-
CADM-140-positive cases have been reported in the Asian
population.6e8,33 Thus, the impact of HRCT pattern on
survival and the associations between HRCT patterns and
MSA profiles may also be different among different ethnic
populations. Further comparative studies among differentethnic populations may be required to determine the clin-
ical significance of anti-CADM and HRCT patterns.
We should mention some limitations of the present study.
First, the study patients did not receive uniform treatment,
although all patients were treated with corticosteroids and
most with additional immunosuppressive agents. Second,
the small study cohort did not allow us to perform multi-
variate analysis and compare the prognostic value of HRCT
patterns versus other parameters in the subgroup of anti-
CADM-140-positive patients. Given the worse prognosis of
anti-CADM-140-positive cases, the prognostic factors in this
subgroup of PM/DM-ILD, including HRCT patterns, should be
further addressed in future studies. Third, radiopathological
correlation was not obtained in our series, although the
significance of pathological diagnosis in clinical practice of
PM/DM-ILD or collagen vascular disease-related ILD has not
been determined.34,35
Despite these limitations, we have demonstrated that
the HRCT pattern at diagnosis can provide significant in-
formation about the prognosis of PM/DM-ILD, as well as the
presence of anti-CADM-140. HRCT evaluation can help
identify the most aggressive phenotypes of PM/DM-ILD at
diagnosis. Further studies with a larger number of patients
are required to determine the prognostic value of HRCT
Figure 1 Comparison of survival between patients with the
lower consolidation/ground-glass attenuation (GGA) pattern and
those with other HRCT patterns. (a) Among all patients (nZ 51),
the prognosis of patients with the lower consolidation/GGA
pattern was significantly worse, compared to those with other
HRCT patterns (log-rank test: P Z 0.02). (b) In anti-CADM-140-
positive patients (n Z 21), the prognosis of patients with the
lower consolidation/GGA pattern was not significantly different
from those with other HRCT patterns (log-rank test: P Z 0.46),
although 90-day mortality was significantly higher in those with
the lower consolidation/GGA pattern (P Z 0.04).
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